AI-guided design of antimalarials with In vitro validation
In this webinar you can hear how a combination of generative chemistry and deep learning has impacted the design of…
In this webinar you can hear how a combination of generative chemistry and deep learning has impacted the design of…
In this webinar, we explore how the limitations of pharmaceutical data can impact conventional predictive model building. Our speakers, Julian Levell (Constellation pharmaceuticals), Ben Irwin and matt Segall (Optibrium) demonstrate how the deep learning imputation algorithm underlying our Cerella platform, overcomes these challenges.
In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares…
This article describes a novel deep learning neural network method and its application for the imputation of bioactivity data, such…
This article is a collaboration with Intellegens, the University of Cambridge and AstraZeneca. It provides a proof-of-concept study in which Cerella™ is used to predict rat in vivo pharmacokinetic (PK) parameters and concentration–time PK profiles.
In this article, the team demonstrates the application of Alchemite™, a deep learning imputation method which underpins our Cerella™ technology, to physicochemical and sensory data.
This article outlines practical applications of deep learning on drug discovery data. It introduces some of the research behind our…
Join Optibrium at HubXchange in Boston to hear more about implementing AI in drug discovery.
Out now in International Biopharmaceutical Industry, Optibrium’s CEO, Dr Matt Segall introduces the concept of augmented intelligence. He explains how to use dynamic…
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
In this study, we identified a new antimalarial with an unusual structure – the only compound in the competition to be proven active, opening up new chemistry for exploration.
OA paper outlining the practical applications of deep imputation on large-scale drug discovery data. It compares deep learning to traditional QSAR methods.
Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses…
In this ebook, you’ll discover the key considerations which every leader needs to take in order to successfully implement AI in their drug discovery pipelines.